Advances in primary cell culture
Historically, primary cells were considered particularly difficult to work with. However, advances in primary cell culture, the availability of commercial primary cells with fully optimized protocols, and new analysis techniques that require less input are making the process easier than ever before.
One of the major advances in cell culture is the transition from 2D to 3D. In a simplified 2D-culture, the tissue-specific architecture, cell-cell interactions, and mechanical/biochemical signalling can be diminished. In turn, the biological relevance of these cultures is limited.
Conversely, 3D cell culture allows cells to grow and interact with a surrounding extracellular framework in all three dimensions. As a result, 3D cultures more closely mimic their original physiological state – allowing cells to interact with each other and the extracellular matrix. This approach has been ground-breaking in areas such as drug discovery and development due to its reliability in predicting in vivo responses. This has culminated in cutting-edge technologies - such as patient-derived organoids and organ-on-a-chip - offering highly contextual models for drug screening and development.
Another limiting factor in primary culture is the generation of enough primary cells for analysis. Generally, this can only be overcome by starting with a greater volume of tissue which may be difficult to attain. However, advances in the sensitivity of analytical tools are offering a solution. For instance, single cell technology – including sequencing, westernblots, and mass cytometry – require very small amounts of starting material, reducing the need to culture large quantities of primary cells.
The future of primary cell culture
Overall, advances in technology are overcoming some of the inherent challenges of primary cell culture. In turn, it is quickly becoming the approach of choice for cellular and molecular biology research and application. Continued primary cell culture developments are set to revolutionize many fields; from vaccine production and organ replacement to stem cell therapies and cancer research.
References
1. Prasad VV, Gopalan RO. Continued use of MDA-MB-435, a melanoma cell line, as a model for human breast cancer, even in year, 2014. npj Breast Cancer 2015 11. 2015;1(1):1-2. doi:10.1038/npjbcancer. 2015.2